Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Drops By 87.7%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) was the recipient of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 1,503 shares, a decrease of 87.7% from the May 31st total of 12,174 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average trading volume of 6,655 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, Zacks Research raised shares of Santen Pharmaceutical to a “hold” rating in a report on Monday, April 13th. One investment analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has an average rating of “Hold”.

Santen Pharmaceutical Stock Performance

Shares of SNPHY stock traded down $0.15 during mid-day trading on Friday, reaching $12.95. 234 shares of the company were exchanged, compared to its average volume of 12,429. The business’s 50 day simple moving average is $11.53 and its 200 day simple moving average is $11.12. The company has a market capitalization of $4.17 billion and a P/E ratio of 0.10. Santen Pharmaceutical has a fifty-two week low of $9.22 and a fifty-two week high of $13.10.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.

With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.